AU1813701A - Interleukin-1 muteins useful as vaccine adjuvants - Google Patents

Interleukin-1 muteins useful as vaccine adjuvants

Info

Publication number
AU1813701A
AU1813701A AU18137/01A AU1813701A AU1813701A AU 1813701 A AU1813701 A AU 1813701A AU 18137/01 A AU18137/01 A AU 18137/01A AU 1813701 A AU1813701 A AU 1813701A AU 1813701 A AU1813701 A AU 1813701A
Authority
AU
Australia
Prior art keywords
mutein
interleukin
muteins
useful
vaccine adjuvants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU18137/01A
Other languages
English (en)
Inventor
Richard S. Dondero
Herman F. Staats
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltech R&D Ltd
Duke University
Original Assignee
Celltech Chiroscience Ltd
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Chiroscience Ltd, Duke University filed Critical Celltech Chiroscience Ltd
Publication of AU1813701A publication Critical patent/AU1813701A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU18137/01A 1999-12-03 2000-12-04 Interleukin-1 muteins useful as vaccine adjuvants Abandoned AU1813701A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16892899P 1999-12-03 1999-12-03
US60168928 1999-12-03
PCT/US2000/032813 WO2001039803A2 (en) 1999-12-03 2000-12-04 Interleukin-1 muteins useful as vaccine adjuvants

Publications (1)

Publication Number Publication Date
AU1813701A true AU1813701A (en) 2001-06-12

Family

ID=22613541

Family Applications (1)

Application Number Title Priority Date Filing Date
AU18137/01A Abandoned AU1813701A (en) 1999-12-03 2000-12-04 Interleukin-1 muteins useful as vaccine adjuvants

Country Status (7)

Country Link
US (2) US6656462B2 (enExample)
EP (1) EP1196193B1 (enExample)
JP (1) JP2003515569A (enExample)
AT (1) ATE413191T1 (enExample)
AU (1) AU1813701A (enExample)
DE (1) DE60040740D1 (enExample)
WO (1) WO2001039803A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270758B1 (en) * 1998-10-08 2001-08-07 Duke University Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
EP1931383A1 (en) 2005-09-28 2008-06-18 Cytos Biotechnology AG Interleukin-1 conjugates and uses thereof
WO2008037504A1 (en) * 2006-09-28 2008-04-03 Cytos Biotechnology Ag Interleukin-1 muteins linked to virus-like particles to treat il-1 associated diseases
EP2368570A3 (en) 2006-01-18 2012-05-02 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
US9138470B2 (en) * 2007-11-02 2015-09-22 The Johns Hopkins University Multi-component L2 vaccine for prevention of human papilloma virus infection
WO2010042481A1 (en) 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
ES2784957T3 (es) 2009-04-03 2020-10-02 Univ Chicago Composiciones y métodos relacionados con variantes de la proteína A (SPA)
US8389474B1 (en) * 2009-07-14 2013-03-05 Alan Anson Wanderer Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion
WO2011100508A2 (en) 2010-02-12 2011-08-18 Arizona Board Of Regents For And On Behalf Of Arizona State University Methods and compositions related to glycoprotein-immunoglobulin fusions
EP2555794A4 (en) 2010-04-05 2014-01-15 Univ Chicago COMPOSITIONS AND METHODS RELATING TO PROTEIN A (SPA) ANTIBODIES AS IMMUNE REACTION AMPLIFIERS
BR112013000097B1 (pt) 2010-07-02 2022-02-01 The University Of Chicago Polipeptídeo imunogênico isolado, composição imunogênica e seu uso
EP2614074A1 (en) 2010-09-09 2013-07-17 The University of Chicago Methods and compositions involving protective staphylococcal antigens
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
WO2013162746A1 (en) 2012-04-26 2013-10-31 University Of Chicago Staphylococcal coagulase antigens and methods of their use
WO2014085767A1 (en) * 2012-11-29 2014-06-05 University Of Rochester Compositions and methods for treating immune conditions, including type1 diabetes
CN104740615A (zh) * 2013-12-31 2015-07-01 上海索菲里奥生物医药科技发展有限公司 IL-1β在制备用于治疗由金黄色葡萄球菌易感所引起的炎症的药物中的用途
TWI601742B (zh) * 2016-03-23 2017-10-11 國立清華大學 使宿主提早產生抗體及延長抗體保護時間的重組雞介白素１β蛋白質及其應用
US10662226B2 (en) 2016-10-28 2020-05-26 The Regents of the University of Caiifomia Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers
WO2019183500A1 (en) 2018-03-23 2019-09-26 Hung Chiung Yu Coccidioides antigens and methods of their use
US20230293652A1 (en) * 2020-07-07 2023-09-21 Orionis Biosciences, Inc. Immunostimulatory adjuvants
US20250177514A1 (en) 2022-01-28 2025-06-05 Pfizer Inc. Coronavirus antigen variants
WO2025027492A1 (en) 2023-07-31 2025-02-06 Pfizer Inc. Coronavirus antigen variants

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342614A (en) * 1984-12-21 1994-08-30 Otsuka Pharmaceutical Co., Ltd. Method of treating arthritus or inflammation with IL-1β or derivatives thereof
US5503841A (en) 1985-09-20 1996-04-02 Cetus Oncology Corporation Human IL-2 as a vaccine adjuvant
JP2591615B2 (ja) * 1986-03-14 1997-03-19 大塚製薬株式会社 インターロイキン−１β誘導体及び医薬
IT1217314B (it) 1987-02-20 1990-03-22 Sclavo Spa Nonapeptide sintetico ad attivita'adiuvante capace di potenziare in vivo la risposta anticorporale
DE69032251T2 (de) * 1989-02-27 1998-08-13 Massachusetts Institute Of Technology, Cambridge, Mass. Il-1, dessen biologische aktivität inhibiert ist
JP3485184B2 (ja) 1989-07-14 2004-01-13 アメリカン サイアナミド カンパニー インターロイキン含有安定ワクチン組成物
AU651949B2 (en) 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines

Also Published As

Publication number Publication date
WO2001039803A3 (en) 2002-02-21
US20040253208A1 (en) 2004-12-16
US20010036452A1 (en) 2001-11-01
JP2003515569A (ja) 2003-05-07
US6656462B2 (en) 2003-12-02
ATE413191T1 (de) 2008-11-15
DE60040740D1 (de) 2008-12-18
EP1196193A2 (en) 2002-04-17
WO2001039803A2 (en) 2001-06-07
EP1196193B1 (en) 2008-11-05

Similar Documents

Publication Publication Date Title
AU1813701A (en) Interleukin-1 muteins useful as vaccine adjuvants
Mahon et al. Interleukin-12 is produced by macrophages in response to live or killed Bordetella pertussis and enhances the efficacy of an acellular pertussis vaccine by promoting induction of Th1 cells
NZ323973A (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
ATE229978T1 (de) Helicobacter proteine und impstoffe
Rotman et al. IL‐12 eliminates the Th‐2 dependent protective immune response of mice to larval Strongyloides stercoralis
MD1586F2 (ro) Inducere a unui raspuns citotoxic T-limfocitar
Schijns et al. Immunoadjuvant activities of E. coli-and plasmid-expressed recombinant chicken IFN-α/β, IFN-γ and IL-1β in 1-day-and 3-week-old chickens
FI920132A0 (fi) Stabila vaccinkompositioner innehaollande interleukiner.
PT1090033E (pt) Particulas de proteinas de envelope do hcv: utilizacao para vacinacao
Lofthouse et al. Cytokines as adjuvants for ruminant vaccines
EP0327640A4 (en) IMMUNOTHERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF ACQUIRED IMMUNODEFICIENCY SYNDROME.
FR2677654B1 (fr) Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv.
Zhu et al. Enhancement of DNA vaccine potency against herpes simplex virus 1 by co-administration of an interleukin-18 expression plasmid as a genetic adjuvant
IS2670B (is) Bóluefni og notkun þar á til meðhöndlunar á blandaðri hreyfitaugahrörnun
DE69919984D1 (de) Interleukin-12 und herpes simplex virusantigen enthaltende impfstoffe
US20170021009A1 (en) Heat Inactivated Poxvirus Improves Vaccination Results
WO2002034287A3 (en) Therapeutic vaccine formulations containing chitosan
CA2372181A1 (en) Adjuvant combination formulations
Follador et al. Immune responses to an inactive vaccine against American cutaneous leishmaniasis together with granulocyte-macrophage colony-stimulating factor
ATE515258T1 (de) Mukosales verabreichungssytem
DK0563254T3 (da) Anvendelse af IL-4 til forstærkning af immunrespons på immunogener i vacciner
Hughes et al. Potentiation of the immune response by cytokines
SE9604296D0 (sv) New pharmaceutical formulation of polypeptides
WO2000006198A3 (en) Adjuvant comprising pulmonary surfactant
NZ250555A (en) Vaccine with enhanced immunogenicity by inclusion of a cytokine

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase